159 related articles for article (PubMed ID: 2531939)
1. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
D'Angelo SV; Gilardoni F; D'Angelo A
Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
[TBL] [Abstract][Full Text] [Related]
2. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
3. A prothrombinase-based assay for detection of resistance to activated protein C.
Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
Johnstone IB; Martin CA
Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
[TBL] [Abstract][Full Text] [Related]
5. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
Mischke R
Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
[TBL] [Abstract][Full Text] [Related]
7. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
8. Cardiolipin enhances protein C pathway anticoagulant activity.
Fernández JA; Kojima K; Petäjä J; Hackeng TM; Griffin JH
Blood Cells Mol Dis; 2000 Apr; 26(2):115-23. PubMed ID: 10753602
[TBL] [Abstract][Full Text] [Related]
9. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S.
van Wijnen M; Stam JG; van't Veer C; Meijers JC; Reitsma PH; Bertina RM; Bouma BN
Thromb Haemost; 1996 Sep; 76(3):397-403. PubMed ID: 8883277
[TBL] [Abstract][Full Text] [Related]
10. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.
Mori T; Takeya H; Nishioka J; Gabazza EC; Suzuki K
Thromb Haemost; 1996 Jan; 75(1):49-55. PubMed ID: 8713779
[TBL] [Abstract][Full Text] [Related]
11. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
12. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
Rosén S; Johansson K; Lindberg K; Dahlbäck B
Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
[TBL] [Abstract][Full Text] [Related]
13. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa.
Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B
Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the anticoagulant activity of protein S by prothrombin.
Mitchell CA; Jane SM; Salem HH
J Clin Invest; 1988 Dec; 82(6):2142-7. PubMed ID: 2974048
[TBL] [Abstract][Full Text] [Related]
15. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
17. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
Koedam JA; Meijers JC; Sixma JJ; Bouma BN
J Clin Invest; 1988 Oct; 82(4):1236-43. PubMed ID: 2971673
[TBL] [Abstract][Full Text] [Related]
19. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation.
Váradi K; Rosing J; Tans G; Pabinger I; Keil B; Schwarz HP
Thromb Haemost; 1996 Aug; 76(2):208-14. PubMed ID: 8865533
[TBL] [Abstract][Full Text] [Related]
20. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
Francis JL; Howard C
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
